Vasorelaxant and Blood Pressure-Lowering Effects of Cnidium monnieri Fruit Ethanol Extract in Sprague Dawley and Spontaneously Hypertensive Rats.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Cnidium*/chemistry ; Plant Extracts*/pharmacology ; Plant Extracts*/chemistry ; Blood Pressure*/drug effects ; Rats, Sprague-Dawley* ; Fruit*/chemistry ; Vasodilator Agents*/pharmacology ; Rats, Inbred SHR* ; Antihypertensive Agents*/pharmacology ; Ethanol*/chemistry ; Furocoumarins*/pharmacology ; Hypertension*/drug therapy ; Hypertension*/physiopathology; Animals ; Rats ; Male ; Vasodilation/drug effects ; Coumarins/pharmacology ; Coumarins/chemistry

Cnidium monnieri (L.) Cusson, a member of the Apiaceae family, is rich in coumarins, such as imperatorin and osthole. Cnidium monnieri fruit (CM) has a broad range of therapeutic potential that can be used in anti-bacterial, anti-cancer, and sexual dysfunction treatments. However, its efficacy in lowering blood pressure through vasodilation remains unknown. This study aimed to assess the potential therapeutic effect of CM 50% ethanol extract (CME) on hypertension and the mechanism of its vasorelaxant effect. CME (1-30 µg/mL) showed a concentration-dependent vasorelaxation on constricted aortic rings in Sprague Dawley rats induced by phenylephrine via an endothelium-independent mechanism. The vasorelaxant effect of CME was inhibited by blockers of voltage-dependent and Ca ²⁺ -activated K ⁺ channels. Additionally, CME inhibited the vascular contraction induced by angiotensin II and CaCl 2 . The main active compounds of CM, i.e., imperatorin (3-300 µM) and osthole (1-100 µM), showed a concentration-dependent vasorelaxation effect, with half-maximal effective concentration values of 9.14 ± 0.06 and 5.98 ± 0.06 µM, respectively. Orally administered CME significantly reduced the blood pressure of spontaneously hypertensive rats. Our research shows that CME is a promising treatment option for hypertension. However, further studies are required to fully elucidate its therapeutic potential.

Int J Mol Sci. 2014 May 28;15(6):9566-78. (PMID: 24879527)
Circ Res. 2014 Feb 28;114(5):754-7. (PMID: 24577962)
Open Cardiovasc Med J. 2010 Dec 23;4:302-12. (PMID: 21339899)
Adv Pharmacol. 2016;77:1-27. (PMID: 27451093)
Biomedicines. 2024 Feb 01;12(2):. (PMID: 38397948)
Adv Clin Exp Med. 2016 Jan-Feb;25(1):173-83. (PMID: 26935512)
Molecules. 2023 Mar 06;28(5):. (PMID: 36903660)
Chem Biol Interact. 2009 Oct 30;181(3):309-15. (PMID: 19682441)
Eur J Pharmacol. 2007 Nov 14;573(1-3):170-5. (PMID: 17662269)
J Tradit Chin Med. 2019 Aug;39(4):492-501. (PMID: 32186096)
Int J Mol Sci. 2022 May 12;23(10):. (PMID: 35628212)
Nutrients. 2023 Oct 24;15(21):. (PMID: 37960162)
Fitoterapia. 2011 Oct;82(7):988-96. (PMID: 21679750)
Lancet. 2021 Sep 11;398(10304):957-980. (PMID: 34450083)
Chin J Physiol. 1996;39(1):1-8. (PMID: 8902298)
Indian J Med Sci. 2007 Nov;61(11):616-24. (PMID: 18025751)
Clin Exp Hypertens. 2017;39(2):133-138. (PMID: 28287882)
Curr Hypertens Rep. 2017 Sep 18;19(9):77. (PMID: 28921053)
Int J Mol Sci. 2014 Mar 04;15(3):3889-903. (PMID: 24599080)
BMC Complement Altern Med. 2015 Oct 31;15:395. (PMID: 26520575)
Evid Based Complement Alternat Med. 2013;2013:350964. (PMID: 24204390)
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997 Apr;17(4):227-9. (PMID: 9863099)
J Ethnopharmacol. 2005 Jan 4;96(1-2):93-7. (PMID: 15588655)
Nat Rev Cardiol. 2021 Nov;18(11):785-802. (PMID: 34050340)
Front Pharmacol. 2020 Apr 07;11:422. (PMID: 32317975)
Fitoterapia. 2010 Dec;81(8):1188-95. (PMID: 20691250)
Planta Med. 2002 Oct;68(10):891-5. (PMID: 12391551)
Fed Proc. 1979 Jan;38(1):66-71. (PMID: 215463)
Int J Mol Sci. 2022 Jun 10;23(12):. (PMID: 35742943)
Front Pharmacol. 2021 Mar 22;12:572463. (PMID: 33828480)
Electrolyte Blood Press. 2008 Jun;6(1):42-50. (PMID: 24459521)
Molecules. 2015 Jun 10;20(6):10721-33. (PMID: 26065836)
Int J Mol Sci. 2020 Feb 03;21(3):. (PMID: 32028721)
J Ethnopharmacol. 2013 May 20;147(2):536-9. (PMID: 23541934)
Biochem Biophys Res Commun. 2008 Dec 12;377(2):504-507. (PMID: 18929540)
Biochem Pharmacol. 2002 Jan 15;63(2):199-206. (PMID: 11841794)
BMC Complement Altern Med. 2017 Oct 2;17(1):474. (PMID: 28969672)
Nutrients. 2021 Aug 15;13(8):. (PMID: 34444956)
Eur J Pharmacol. 2019 Jun 5;852:244-253. (PMID: 30965056)
Planta Med. 2001 Apr;67(3):282-4. (PMID: 11345705)
Eur J Pharmacol. 1992 Aug 14;219(1):29-34. (PMID: 1327835)
Adv Pharmacol. 2017;78:89-144. (PMID: 28212804)
J Renal Inj Prev. 2016 Aug 09;5(3):123-8. (PMID: 27689107)
Korean J Anesthesiol. 2014 Feb;66(2):143-52. (PMID: 24624273)
Int J Mol Sci. 2014 Mar 17;15(3):4608-18. (PMID: 24642881)
Brain Res. 2012 Jan 18;1433:127-36. (PMID: 22153917)
Am J Transl Res. 2019 Jan 15;11(1):142-159. (PMID: 30787975)
Avicenna J Phytomed. 2020 Jul-Aug;10(4):407-416. (PMID: 32850297)
Int J Mol Sci. 2023 Jan 06;24(2):. (PMID: 36674685)
Molecules. 2019 Dec 24;25(1):. (PMID: 31878172)
J Ethnopharmacol. 2010 Aug 9;130(3):545-51. (PMID: 20669368)

Keywords: Cnidium monnieri fruit; hypertension; imperatorin; osthole; vasorelaxation

0 (Plant Extracts)
0 (Vasodilator Agents)
0 (Antihypertensive Agents)
3K9958V90M (Ethanol)
0 (Furocoumarins)
XH1TI1759C (osthol)
K713N25C78 (imperatorin)
0 (Coumarins)

Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240429

20250114

PMC11050430

10.3390/ijms25084223

38673809